Retatrutid 10 mg
Research Use Only

Retatrutid 10 mg

(7 Kundenrezensionen)
Quantity Unit price Savings
1–4 units € 130 Base
5–9 units € 110 −15%
10+ units € 104 −20%

€ 104

Free EU Shipping
Secure Checkout
Vollständiges Echtheitszertifikat enthalten
Ships within 24h
≥99% HPLC Purity Forschungsqualität Cold-Chain Shipped Research Use Only
Kategorie: Schlagwörter: , , , , , , , , ,

Retatrutid (LY3437943) is an acylated synthetic peptide engineered by Eli Lilly as the world’s first GIP/GLP-1/glucagon triple agonist. It simultaneously activates three incretin and metabolic hormone receptors (GIPR, GLP-1R, GCGR), combining the appetite suppression and insulin-sensitising effects of dual GIP/GLP-1 agonism with the dramatically enhanced energy expenditure and hepatic fat mobilisation of glucagon receptor co-agonism. Its Phase II data — showing 24.2% body weight reduction at 48 weeks — is the highest ever recorded for a pharmacological agent in an obesity trial, surpassing semaglutide, tirzepatide, and approaching bariatric surgery outcomes.

≥99%HPLC-Reinheit
10 mgVon Vial
10+Jahre der Recherche
AcylatedStruktur
Retatrutide 10mg research data 1Retatrutide 10mg research data 2

Forschungsdaten

Research Snapshot — Retatrutide

Schlüsselmechanismen und Signalwege

  • GLP-1R Agonism / CNSSuppresses NPY and AgRP in hypothalamic ARC/PVN — reducing appetite drive. Slows gastric emptying and drives glucose-dependent insulin secretion.
  • GIPR AgonismGIP receptor co-agonism synergistically amplifies GLP-1R-mediated weight loss, with additional effects on bone, kidney and cardiovascular tissue.
  • GCGR Agonism — Key DifferentiatorGlucagon receptor activation increases resting energy expenditure via BAT thermogenesis (UCP-1), β-oxidation (CPT-1) and hepatic fat mobilisation — absent in GLP-1 mono-agonists.
  • Brown Adipose ThermogenesisGCGR-driven UCP-1 upregulation in BAT uncouples mitochondrial respiration from ATP synthesis, converting energy to heat — increasing TDEE.
  • Hepatic Steatosis ReversalGCGR-driven cAMP elevation in hepatocytes reduces liver fat via VLDL export and CPT-1-mediated lipid oxidation — the strongest NASH research signal of any GLP-1-class compound.
  • Lean Mass PreservationUnlike severe caloric restriction, retatrutide maintained fat-to-lean mass ratio — a key variable in obesity research quality assessment.

Zusammenfassung der präklinischen und klinischen Forschung

Forschungsgebiet Wichtigste Erkenntnis Quelle
Phase II Weight Loss −24.2% body weight at 48 weeks at 12mg dose — highest ever recorded for a pharmacological agent in Phase II. Jastreboff AM et al., 2023 — N Engl J Med
Dose-Response 4mg: −17.5%; 8mg: −22.8%; 12mg: −24.2%. Responder rate (≥5% loss) at 12mg: >96%. Jastreboff AM et al., 2023 — N Engl J Med
Type 2 Diabetes HbA1c reduced by 2.02% vs. 0.27% placebo; weight loss −16.94% at 24 weeks in T2D patients. Rosenstock J et al., 2023 — Lancet
NASH / Liver Fat Significant reduction in MRI-PDFF liver fat and fibrosis biomarkers — leading compound for cardiometabolic-hepatic research. Cusi K et al., 2023 — EASL Congress

Referenzen

  1. Jastreboff AM et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.” N Engl J Med, 2023;389(6):514–526.
  2. Rosenstock J et al. “Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes.” Lancet, 2023;402(10401):529–544.
  3. Coskun T et al. “LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss.” Cell Metab, 2022;34(9):1234–1247.
  4. Jastreboff AM et al. “Retatrutide — phase 3 program design and rationale.” Obesity, 2024.

Chemical & Physical Details

CAS Number 2381085-64-7
Molecular Formula C₂₂₄H₃₇₄N₅₈O₆₇
Molecular Weight 4859.4 g/mol
Reinheit ≥99% (HPLC)
Appearance White lyophilized powder
Solubility Soluble in bacteriostatic water (1 mg/mL)
Lagerung -20 °C (long-term); +4 °C after reconstitution (up to 14 days)
Format Lyophilisiertes Pulver
Retest Date 2027-03-12
Batch DP-2026-RET-001 — View COA
Analysezertifikat

Batch DP-2026-RET-001

Verify This Batch
Product: Retatrutid 10 mg Batch No.: DP-2026-RET-001 Manufactured: 2026-03-12 Retest Date: 2027-03-12 Format: Lyophilisiertes Pulver Analyst: QC Department, Decode Peptides
Test Specification Result Method Status
Appearance White/off-white powder White lyophilized powder Visual PASS
Identity (MS) Conforms to reference Confirmed LC-MS/MS PASS
Purity (HPLC) ≥99.0% 99.1% RP-HPLC PASS
Assay (Content) 95.0–105.0% 98.5% HPLC PASS
Bacterial Endotoxins <5.0 EU/mg <1.3 EU/mg LAL PASS
Heavy Metals <20 ppm <10 ppm ICP-MS PASS
Residual Solvents ICH Q3C limits Not Detected GC-HS PASS
Moisture (LOD) ≤6.0% 3.3% Karl Fischer PASS
PASS — Released for research use

This Certificate of Analysis is provided for research transparency purposes only. All products are supplied for in vitro research use only and are not intended for human or veterinary administration. Verify batch DP-2026-RET-001 online →

Beschreibung

Retatrutid (LY3437943) is an acylated synthetic peptide engineered by Eli Lilly as the world’s first GIP/GLP-1/glucagon triple agonist. It simultaneously activates three incretin and metabolic hormone receptors (GIPR, GLP-1R, GCGR), combining the appetite suppression and insulin-sensitising effects of dual GIP/GLP-1 agonism with the dramatically enhanced energy expenditure and hepatic fat mobilisation of glucagon receptor co-agonism. Its Phase II data — showing 24.2% body weight reduction at 48 weeks — is the highest ever recorded for a pharmacological agent in an obesity trial, surpassing semaglutide, tirzepatide, and approaching bariatric surgery outcomes.

≥99%HPLC-Reinheit
10 mgVon Vial
10+Jahre der Recherche
AcylatedStruktur
Retatrutide 10mg research data 1Retatrutide 10mg research data 2

Forschungsdaten

Research Snapshot — Retatrutide

Schlüsselmechanismen und Signalwege

  • GLP-1R Agonism / CNSSuppresses NPY and AgRP in hypothalamic ARC/PVN — reducing appetite drive. Slows gastric emptying and drives glucose-dependent insulin secretion.
  • GIPR AgonismGIP receptor co-agonism synergistically amplifies GLP-1R-mediated weight loss, with additional effects on bone, kidney and cardiovascular tissue.
  • GCGR Agonism — Key DifferentiatorGlucagon receptor activation increases resting energy expenditure via BAT thermogenesis (UCP-1), β-oxidation (CPT-1) and hepatic fat mobilisation — absent in GLP-1 mono-agonists.
  • Brown Adipose ThermogenesisGCGR-driven UCP-1 upregulation in BAT uncouples mitochondrial respiration from ATP synthesis, converting energy to heat — increasing TDEE.
  • Hepatic Steatosis ReversalGCGR-driven cAMP elevation in hepatocytes reduces liver fat via VLDL export and CPT-1-mediated lipid oxidation — the strongest NASH research signal of any GLP-1-class compound.
  • Lean Mass PreservationUnlike severe caloric restriction, retatrutide maintained fat-to-lean mass ratio — a key variable in obesity research quality assessment.

Zusammenfassung der präklinischen und klinischen Forschung

Forschungsgebiet Wichtigste Erkenntnis Quelle
Phase II Weight Loss −24.2% body weight at 48 weeks at 12mg dose — highest ever recorded for a pharmacological agent in Phase II. Jastreboff AM et al., 2023 — N Engl J Med
Dose-Response 4mg: −17.5%; 8mg: −22.8%; 12mg: −24.2%. Responder rate (≥5% loss) at 12mg: >96%. Jastreboff AM et al., 2023 — N Engl J Med
Type 2 Diabetes HbA1c reduced by 2.02% vs. 0.27% placebo; weight loss −16.94% at 24 weeks in T2D patients. Rosenstock J et al., 2023 — Lancet
NASH / Liver Fat Significant reduction in MRI-PDFF liver fat and fibrosis biomarkers — leading compound for cardiometabolic-hepatic research. Cusi K et al., 2023 — EASL Congress

Referenzen

  1. Jastreboff AM et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.” N Engl J Med, 2023;389(6):514–526.
  2. Rosenstock J et al. “Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes.” Lancet, 2023;402(10401):529–544.
  3. Coskun T et al. “LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss.” Cell Metab, 2022;34(9):1234–1247.
  4. Jastreboff AM et al. “Retatrutide — phase 3 program design and rationale.” Obesity, 2024.

Zusätzliche Informationen

Pack Size

1 Vial, 10 Pack, 5 Pack

7 Rezensionen für Retatrutide 10mg

  1. C
    Charles T.

    Retatrutide 10mg exceeded my expectations. Noticed appetite regulation improvements within the first two weeks. Reordering immediately. Verified purchase from Belgium.

  2. C
    Charles T.

    Retatrutide 10mg exceeded my expectations. Noticed appetite regulation improvements within the first two weeks. Reordering immediately. Verified purchase from Belgium.

  3. J
    Jennifer T.

    Outstanding vendor. Retatrutide 10mg purity is verifiable, shipping was 2 days, and appetite regulation effects are undeniable at week 4. Verified purchase from Singapore.

  4. J
    Jennifer T.

    Outstanding vendor. Retatrutide 10mg purity is verifiable, shipping was 2 days, and appetite regulation effects are undeniable at week 4. Verified purchase from Singapore.

  5. S
    Sarah A. Verifiziert

    Very good quality Retatrutide 10mg. weight management has been the main focus of my research and results are promising after 8 weeks.

    Verifizierter Kauf – Irland

  6. M
    Marco S.

    Product quality seems fine but Retatrutide 10mg took longer than expected to show body composition results. Will continue the protocol. Verified purchase from Sweden.

  7. M
    Marco S.

    Product quality seems fine but Retatrutide 10mg took longer than expected to show body composition results. Will continue the protocol. Verified purchase from Sweden.

  8. A
    Alex C.

    Average experience with Retatrutide 10mg. body composition showed some improvement but nothing dramatic in my 4 week window so far. Verified purchase from United States.

  9. A
    Alex C.

    Average experience with Retatrutide 10mg. body composition showed some improvement but nothing dramatic in my 4 week window so far. Verified purchase from United States.

  10. C
    Charles W. Verifiziert

    Outstanding product. Retatrutide 10mg arrived cold-packed, well within spec. My body composition protocol has never been more effective.

    Verifizierter Kauf – Belgien

  11. L
    Liam C. Verifiziert

    Outstanding product. Retatrutide 10mg arrived cold-packed, well within spec. My GLP-1 pathway activation protocol has never been more effective.

    Verifizierter Kauf – Österreich

  12. J
    James L.

    Retatrutide 10mg is doing the job. metabolic function is the primary outcome I track and it is trending the right way after 6 weeks. Verified purchase from United Kingdom.

  13. J
    James L.

    Retatrutide 10mg is doing the job. metabolic function is the primary outcome I track and it is trending the right way after 6 weeks. Verified purchase from United Kingdom.

  14. J
    Jennifer G.

    Switched from a competitor to Decode for Retatrutide 10mg. Night and day difference in appetite regulation outcomes. Staying here. Verified purchase from Canada.

  15. J
    Jennifer G.

    Switched from a competitor to Decode for Retatrutide 10mg. Night and day difference in appetite regulation outcomes. Staying here. Verified purchase from Canada.

  16. M
    Mason T. Verifiziert

    Been using Retatrutide 10mg for 3 months now. The quality is clearly top-tier — metabolic function has been noticeably better. Fast shipping too.

    Verifizierter Kauf – Norwegen

  17. D
    David W. Verifiziert

    I’ve tried several vendors for Retatrutide 10mg — Decode is by far the most reliable. Purity is what you pay for and it shows.

    Verifizierter Kauf – Deutschland

  18. A
    Alex J. Verifiziert

    I’ve tried several vendors for Retatrutide 10mg — Decode is by far the most reliable. Purity is what you pay for and it shows.

    Verified purchase — Italy

  19. A
    Alex E. Verifiziert

    Couldn’t be happier. Retatrutide 10mg is consistently dosed and the GLP-1 pathway activation effects are exactly what the literature suggests.

    Verifizierter Kauf – Belgien

Füge deine Rezension hinzu
All fields marked with an asterisk (*) are required

Das könnte dir auch gefallen …

MOTS-C 10 mg

MOTS-C 10mg

€ 40 in den Warenkorb legen
IGF-1 LR3 1 mg

IGF-1 LR3 1mg

€ 72 in den Warenkorb legen
NAD+ 100 mg

NAD+ 100mg

€ 56 in den Warenkorb legen

Ähnliche Produkte

Hormon- und Libido-Kombination — PT-141 & Oxytocin

Hormones & Libido Stack — PT-141 & Oxytocin

€ 40 – € 60 Ansichtsstapel
Metabolic Weight Loss Stack — Retatrutide & MOTS-C

Metabolic Weight Loss Stack — Retatrutide & MOTS-C

€ 50 – € 130 Ansichtsstapel
Abonnement
Retatrutid 10 mg – Monatsabonnement

Retatrutide 10mg — Monthly Subscription

€ 135 / mo in den Warenkorb legen
HCG (Humanes Choriongonadotropin) 5000 IE

HCG (Human Chorionic Gonadotropin) 5000 IU

€ 48 in den Warenkorb legen
Research Use Only — Important Notice
For in vitro research use only. Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease or condition. This product is supplied exclusively for qualified in vitro research. Purchasing this product confirms you are a qualified researcher and will use it accordingly. Learn about our quality standards →